JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future

Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis (RA) and other immune-mediated diseases, placing alongside or even replacing conventional and biological drugs. JAKi are c...

Descripción completa

Detalles Bibliográficos
Autores principales: Angelini, Jacopo, Talotta, Rossella, Roncato, Rossana, Fornasier, Giulia, Barbiero, Giorgia, Dal Cin, Lisa, Brancati, Serena, Scaglione, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408575/
https://www.ncbi.nlm.nih.gov/pubmed/32635659
http://dx.doi.org/10.3390/biom10071002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408575/
https://www.ncbi.nlm.nih.gov/pubmed/32635659
http://dx.doi.org/10.3390/biom10071002

Ejemplares similares